Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

18/06/2020 Eurecat, at the cutting edge of plastronics 03/06/2020 Barcelona will be connected to one of the longest subsea fiber optic cable in the world 20/05/2020 Hub B30: a useful platform 07/05/2020 We are a territory of innovation 16/04/2020 Alba synchrotron: the double life of electrons 02/04/2020 Alba synchrotron: 10 years at the service of the society
1 2 3 4 5 6 7 8 9 10